Sign up to save your podcasts
Or
Share Experts Talk AML #5: Venetoclax-based Regimens in Routine Practice
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Experts Talk AML #5: Venetoclax-based Regimens in Routine Practice
A discussion between Dr. Daniel A. Pollyea and Dr. Courtney DiNardo, moderated by Dr. Michelle Geddes (May 2022)
In this first episode, Dr. Daniel Pollyea and Dr. Courtney DiNardo compare their approaches to managing AML with venetoclax-based therapies, while Dr. Michelle Geddes provides a Canadian perspective. The focus is on the use of antimicrobial prophylaxis, the management of cytopenia, and the relevance of bone marrow assessments. The experts describe how different factors, from the environment to patient fitness and underlying disease characteristics, play a role in selecting appropriate prophylactic and therapeutic approaches.
Daniel A. Pollyea, MD, MS, Associate Professor of Medicine, Clinical Director of Leukemia Services, Robert H. Allen MD Chair in Hematology Research, Division of Hematology, University of Colorado, School of Medicine
Courtney DiNardo, MD, MSCE, Associate Professor of Medicine, Department of Leukemia, Division of Cancer Medicine, The University of Texas, MD Anderson Cancer Center, Houston, Texas
Michelle Geddes, MD, FRCPC, Clinical Associate Professor, Division of Hematology and Hematologic Malignancies, Department of Medicine, Department of Oncology, University of Calgary
This podcast is intended for Healthcare Professionals only. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities. This program was made possible through Master Clinician Alliance, which graciously acknowledges the educational grant and in-kind support provided by AbbVie Corporation.
View all episodes
By Various Topics on AML and CLL ManagementA discussion between Dr. Daniel A. Pollyea and Dr. Courtney DiNardo, moderated by Dr. Michelle Geddes (May 2022)
In this first episode, Dr. Daniel Pollyea and Dr. Courtney DiNardo compare their approaches to managing AML with venetoclax-based therapies, while Dr. Michelle Geddes provides a Canadian perspective. The focus is on the use of antimicrobial prophylaxis, the management of cytopenia, and the relevance of bone marrow assessments. The experts describe how different factors, from the environment to patient fitness and underlying disease characteristics, play a role in selecting appropriate prophylactic and therapeutic approaches.
Daniel A. Pollyea, MD, MS, Associate Professor of Medicine, Clinical Director of Leukemia Services, Robert H. Allen MD Chair in Hematology Research, Division of Hematology, University of Colorado, School of Medicine
Courtney DiNardo, MD, MSCE, Associate Professor of Medicine, Department of Leukemia, Division of Cancer Medicine, The University of Texas, MD Anderson Cancer Center, Houston, Texas
Michelle Geddes, MD, FRCPC, Clinical Associate Professor, Division of Hematology and Hematologic Malignancies, Department of Medicine, Department of Oncology, University of Calgary
This podcast is intended for Healthcare Professionals only. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities. This program was made possible through Master Clinician Alliance, which graciously acknowledges the educational grant and in-kind support provided by AbbVie Corporation.